AstraZeneca Q2 FY26: Revenue up 37%, PAT up 41% on year

Revenue Growth 20pctPat Growth 25pctExceptional ItemNegative Operating CashflowResults View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹9012.00

prior close

₹9201.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%+0.7% vs market

Pharmaceuticals peers, median of 155sector-0.1%+0.4% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.7

15m

-2.0

30m

-3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3-0.4+0.7-0.1+0.4

Next day

+1.3-0.6+2.0-0.8+2.1

+2.8+0.3+2.5+0.2+2.6

+2.0+0.2+1.8-0.0+2.0

+1.7+0.1+1.6+0.2+1.5

+1.4+0.7+0.7+0.3+1.1

+0.8-0.3+1.1-0.9+1.6

15d

+0.3-2.0+2.3-1.5+1.7

-0.4-5.7+5.2-3.8+3.4

-9.4-7.8-1.6-6.2-3.2

-0.1-4.6+4.5-6.9+6.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India posted Q2 FY26 revenue of Rs 559 crore, up 37% from Rs 408 crore a year ago. Half-year revenue grew to Rs 1,085 crore from Rs 796 crore. Q2 profit after tax rose to Rs 54.2 crore versus Rs 38.4 crore. H1 PAT jumped to Rs 110 crore from Rs 27 crore. The firm booked a Rs 5.3 crore exceptional charge for its Bangalore manufacturing site, shut down in June 2025 and now held for sale. H1 operating cash flow turned negative at Rs 66 crore versus positive Rs 38 crore earlier.

Likely market impact

Strong topline and profit growth, but negative H1 operating cash flow and Bangalore plant exit deserve attention.